| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
Resorantel targets gastrointestinal nematodes and other parasitic worms in animals. As an anthelmintic, it acts against parasites such as Haemonchus, Ostertagia, Trichostrongylus species, and paramphistomes. The exact mechanism of action involves disruption of parasite metabolism or neuromuscular function, leading to paralysis and elimination of the worms from the host.
|
|---|---|
| ln Vitro |
In vitro activity of resorantel is demonstrated by its anthelmintic properties against various gastrointestinal nematodes. The compound shows efficacy against Haemonchus, Ostertagia, and Trichostrongylus species. Its activity is typically assessed in standard anthelmintic susceptibility assays using nematode cultures or isolated parasite preparations.
|
| ln Vivo |
In naturally infected sheep, resorantel (65 mg/kg, a single oral dose) is effective against paramphistomiasis[1].
In vivo activity of resorantel has been demonstrated in veterinary applications for treating parasitic infections in cattle, sheep, and other ruminants. It is used to treat paramphistomiasis and infections caused by gastrointestinal nematodes. The compound is effective in reducing parasite burden and improving the health of infected animals. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for resorantel are not typically performed, as it is an anthelmintic whose mechanism involves disruption of parasite physiology rather than specific enzyme inhibition. Anthelmintic activity is assessed using standard parasite motility assays or egg hatch tests.
|
| Cell Assay |
In vitro cellular assays for resorantel involve culturing nematode larvae or adult worms in the presence of varying concentrations of the compound. Anthelmintic activity is assessed by measuring inhibition of motility, development, or survival of the parasites.
|
| Animal Protocol |
Animal/Disease Models: Five flocks of sheep in different villages of Haryana[1].
Doses: 65 mg/kg. Route of Administration: A single oral dose. Experimental Results: None of the treated sheep died of enteric paramphistomiasis. The clinical disappeared within 2 to 3 days of the treatment and their appetite and general condition improved. No ill effects of the drug were noticed. Of the untreated sheep, 35 % died with a range of 24-52 % in the different flocks. Many of the other untreated sheep continued to exhibit clinical signs of paramphistomiasis. In vivo animal experiments for resorantel involve administering the compound to livestock (cattle, sheep) infected with gastrointestinal nematodes or paramphistomes. Efficacy is evaluated by measuring fecal egg count reduction, parasite burden in tissues, and clinical improvement of the animals. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for resorantel indicate that it is insoluble in water, hydrocarbons, and vegetable oils. The compound has a melting point of 229-230°C. Its absorption, distribution, metabolism, and excretion properties in animals have not been fully characterized. The compound is used in veterinary medicine.
|
| Toxicity/Toxicokinetics |
Toxicological data for resorantel are limited. As a veterinary anthelmintic, it is generally considered safe for use in animals at therapeutic doses. The compound is intended for veterinary use only and is not for human therapeutic application. Standard safety precautions should be followed when handling this compound.
|
| References |
[1]. R P Gupta, et al. Efficacy of resorantel against paramphistomiasis in naturally infected sheep. Trop Anim Health Prod. 1981 Feb;13(1):35-6.
[2]. Swan GE. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. J S Afr Vet Assoc. 1999;70(2):61-70. |
| Additional Infomation |
Resorantel (CAS#: 20788-07-2) has a molecular weight of 308.13. It is an anthelmintic agent used in veterinary medicine to treat gastrointestinal nematode infections and paramphistomiasis in cattle and sheep. The compound is for research and veterinary use only.
|
| Molecular Formula |
C13H10BRNO3
|
|---|---|
| Molecular Weight |
308.13
|
| Exact Mass |
306.984
|
| CAS # |
20788-07-2
|
| PubChem CID |
65696
|
| Appearance |
White to off-white solid powder
|
| Density |
1.699g/cm3
|
| Boiling Point |
391.1ºC at 760mmHg
|
| Flash Point |
190.4ºC
|
| Vapour Pressure |
1.12E-06mmHg at 25°C
|
| Index of Refraction |
1.728
|
| LogP |
3.185
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
282
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=C([H])C(=C([H])C=1[H])N([H])C(C1C(=C([H])C([H])=C([H])C=1O[H])O[H])=O
|
| InChi Key |
IHYNKGRWCDKNEG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10BrNO3/c14-8-4-6-9(7-5-8)15-13(18)12-10(16)2-1-3-11(12)17/h1-7,16-17H,(H,15,18)
|
| Chemical Name |
N-(4-bromophenyl)-2,6-dihydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (811.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2454 mL | 16.2269 mL | 32.4538 mL | |
| 5 mM | 0.6491 mL | 3.2454 mL | 6.4908 mL | |
| 10 mM | 0.3245 mL | 1.6227 mL | 3.2454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
